Drugs / human fetal-derived Neural Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03269071 | May 2017 → Jul 2021 | multiple sclerosis | IRCCS San Raffaele | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human fetal-derived Neural Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03269071 ↗ |
| Known as | hNSCs | “The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).” NCT03269071 ↗ |
| Modality | Cell therapy | “The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law).” NCT03269071 ↗ |
| Route | Intrathecal | “The product will be administered intrathecally through lumbar puncture.” NCT03269071 ↗ |